<DOC>
	<DOCNO>NCT00242008</DOCNO>
	<brief_summary>The purpose trial ass whether possible subject idiopathic Parkinson 's Disease switch ropinirole , pramipexole cabergoline rotigotine transdermal system ( SPM 962 ) overnight without worsen Parkinson 's Disease symptom . Subjects meet eligibility criterion switch overnight treatment rotigotine transdermal patch dose consider equivalent dose dopamine agonist subject currently take . Subjects ropinirole pramipexole take last dose bedtime apply rotigotine patch ( e ) upon awaken next morning . Subjects cabergoline apply rotigotine patch 24 hour final dose cabergoline . Subjects continue rotigotine treatment 28 day , dose increase decreased need . At end treatment , subject select enroll open-label extension trial . The first subject enrol 28 December 2004 . The last subject enrol June 2005 last subject visit conduct July 2005 . This study close .</brief_summary>
	<brief_title>A Trial To Assess Switching From Ropinirole , Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Idiopathic Parkinson 's disease Not take dopamine agonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>IDIOPATHIC PARKINSON 'S DISEASE</keyword>
</DOC>